A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.
about
Chinese herbal medicine and interferon in the treatment of chronic hepatitis B: a meta-analysis of randomized, controlled trialsPrevalence and determinants of diabetes mellitus among Iranian patients with chronic liver diseaseHepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizonAnti-HBV Drugs: Progress, Unmet Needs, and New HopeAlcohol and liver cancer: a systematic review and meta-analysis of prospective studiesHepatitis C virus infection and type 1 and type 2 diabetes mellitusConcise review of recent studies in vitiligoA randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis CInterferon therapy in hepatitis C leading to chronic type 1 diabetesInduction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis CCost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United StatesDiagnosis, management, and treatment of hepatitis C: an updatePegylated interferon de novo-induce autoimmune haemolytic anaemia in chronic hepatitis C patient.Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin.Safety, Tolerability, and Immunogenicity of InterferonsTreatment of hepatitis C virus infection and associated vascular complications: a literature review.Animal models to improve our understanding and treatment of suicidal behaviorRNA Interference inhibits hepatitis B virus of different genotypes in vitro and in vivoPneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literaturePsychiatric clearance for patients started on interferon-alpha-based therapies.Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy.Adverse effects and other safety aspects of the hepatitis C antivirals.Successful natural interferon-β plus ribavirin therapy in a chronic hepatitis C patient after discontinuation of interferon-α treatment due to arrhythmia and interstitial pneumonia.Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.Treatment of hepatitis C virus infectionSimultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C.Coeliac disease and C virus-related chronic hepatitis: a non association.Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysisCancer epidemiology and control in Taiwan: a brief review.Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot studySevere exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review.Hepatitis C and human immunodeficiency virus infection.Viral pathogenesis of hepatocellular carcinoma.Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysisRegulatory T cells resist virus infection-induced apoptosisPegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.Protracted anaphylaxis developed after peginterferon α-2a administration for chronic hepatitis C.Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy.Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer
P2860
Q24544204-B2911002-3790-4F11-B7A1-842A71683289Q24804864-6426924F-D553-4C99-B5BB-4425C82044FAQ26773201-FE0525F6-5155-4B18-A845-C836D89B5AB3Q26782742-8377DBA0-4492-4038-BAD0-9980CE699C90Q26828925-0BD64883-401B-4752-8840-B241465F1B86Q26829202-95330E0E-BE36-40F7-BA29-4F6B23DA11D1Q27025963-E751F797-6180-4CCF-974E-41F50CB3B61BQ27478337-9A5CC619-5F3E-4374-826F-69672EC37106Q28080876-70270A4C-BECA-436D-B9D1-D5AB91C25D1DQ28348712-7CE28F9B-DC4E-40BA-843F-7EE548653B38Q28488762-1196E0D9-AECE-4BC4-885A-45CCEC0848C9Q29619682-688FE2D1-4E8A-4A16-B25E-464E376755A1Q33161405-5F67F4F4-B134-41FE-914B-3C06C5D9D66FQ33401381-879461EE-AE1E-4B58-BB2B-3F39C9BB8B14Q33408043-C16BC60E-137E-4681-8838-13FDE0C8B7A0Q33435810-CA101F46-E642-4320-A6F9-61F22C5449CCQ33635003-01717226-B5AA-4A00-9769-0136B8904CC1Q33635653-9EA49EA9-6CD9-4826-8413-C462C6B43123Q33653027-27EF7682-6201-4750-8534-5770572DAB50Q33658701-29A81BC9-D1C3-4AEB-8983-1AE3A5E0E182Q33708662-3EDCE1CB-9D35-430C-A4A8-6D3B9C4F3528Q33973488-F75CD851-3CA0-4FA3-BAA4-4AA61521D43DQ33988126-D9FABF55-2D25-4FF7-A369-D9192180CC2CQ34012417-F0FD2FB1-E51B-4E64-A043-B0D705C439B3Q34098870-B5B71FC6-A547-4E55-B829-A40761FCD365Q34099424-49CF2B23-00E0-48CC-AE7D-1A6AAA665DE1Q34099620-3273F886-F7C5-44EC-B5F5-908EF69D7789Q34420816-5E20D057-95B0-48C8-9C82-89A79D6B44B3Q34577136-68C6BB21-9263-40D4-A585-7D2DD89FC92EQ34604977-ABEF088E-A0CE-46C2-A341-207F8E5E48DFQ34605699-B402A093-C1A5-47BB-8D65-282A2AA4ABC6Q34737065-67D6592A-27DA-4DD3-82C2-3FDF59362387Q34984125-8BBDFCCD-464B-4D8A-92B1-B9E420132437Q35020878-AC26DF63-2811-449C-9B63-0EE2DB1F8FC2Q35037688-2E27676E-7B4D-41A8-806F-C8D5B5E12779Q35115564-7B3A1F81-4979-4A05-A24D-0B44C0CA3F85Q35124697-95E16BD6-63A1-4590-B937-C879D868449FQ35152412-1944C1CC-0AD4-49C0-97B3-AE35601BB680Q35216879-B6A8AC52-E64D-4EDF-AA10-48DD03EA2D21Q35237312-71A9FFD3-CE59-41A0-A55E-1BD92A608CBD
P2860
A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
A survey of adverse events in ...... treated with alfa interferon.
@en
A survey of adverse events in ...... treated with alfa interferon.
@nl
type
label
A survey of adverse events in ...... treated with alfa interferon.
@en
A survey of adverse events in ...... treated with alfa interferon.
@nl
prefLabel
A survey of adverse events in ...... treated with alfa interferon.
@en
A survey of adverse events in ...... treated with alfa interferon.
@nl
P2093
P1476
A survey of adverse events in ...... treated with alfa interferon.
@en
P2093
P356
10.1016/S0168-8278(96)80184-X
P577
1996-01-01T00:00:00Z